Atopic dermatitis (AD) — a chronic, relapsing inflammatory skin disease characterized by intense pruritus, skin barrier dysfunction, and immune dysregulation — affects approximately 18% of children and 7% of adults in the United States, with a profound impact on quality of life disproportionate to its classification as a "skin condition." For decades, management relied on topical corticosteroids and calcineurin inhibitors that provided symptomatic relief but did not modify the underlying Type 2 inflammatory pathway driving chronic disease. The approval of dupilumab in 2017 — the first biologic agent specifically targeting the IL-4/IL-13 pathway central to AD pathogenesis — ushered in a new era of targeted AD therapy that has continued to expand rapidly through 2025.
The IL-4/IL-13 Pathway: Disease Mechanism
AD's immunological signature is dominated by Type 2 inflammation: IL-4 and IL-13 (sharing the IL-4Rα receptor subunit) drive IgE class switching, TSLP and IL-33 amplification of allergic inflammation, downregulation of skin barrier proteins (filaggrin, loricrin, involucrin), impaired antimicrobial peptide expression (explaining S. aureus susceptibility), and intense pruritus through direct sensitization of sensory neurons. This understanding — that AD is a systemic immune disease manifesting in the skin, rather than simply a skin disease — provided the rationale for biologic therapy targeting the immune pathway rather than the downstream inflammatory symptoms.
Dupilumab (Dupixent): The Reference Standard
Dupilumab (Sanofi/Regeneron) — a fully human monoclonal antibody targeting IL-4Rα, blocking both IL-4 and IL-13 signaling — received FDA approval for moderate-to-severe AD in adults (2017), adolescents (2019), children 6–11 (2020), and infants 6 months–5 years (2022). Phase 3 SOLO 1/2 trials: 36–38% of patients achieved IGA 0/1 (clear/almost clear skin) at 16 weeks versus 8–10% placebo; >50% reduction in EASI score in 44–51% versus 12–15% placebo. Long-term data through 3 years shows sustained response with no new safety signals. Primary adverse effects: injection site reactions and conjunctivitis (10–15% — mechanism involving IL-4/IL-13 in conjunctival goblet cell regulation). Dupilumab has since received approval for asthma, EoE, CRS with nasal polyps, and prurigo nodularis — reflecting the broad Type 2 inflammation targeting across conditions.
JAK Inhibitors: Fast-Onset Alternatives
JAK (Janus kinase) inhibitors — upadacitinib (Rinvoq), abrocitinib (Cibinqo), baricitinib (Olumiant) — are FDA-approved oral small-molecule agents for moderate-to-severe AD refractory to topical therapy. Their advantage over biologics: oral administration and faster onset of action (itch improvement often within 24–48h versus 2–4 weeks for dupilumab). The HEADS UP trial found upadacitinib 30mg/day significantly superior to dupilumab 300mg Q2W at 16 weeks on multiple endpoints. Safety considerations: JAK inhibitors carry class warnings for serious infections, malignancy, MACE, thrombosis, and mortality in rheumatoid arthritis studies — driving FDA's black box warning, though AD-specific populations have a different baseline risk profile than RA patients. Healthcare facilities managing patients with AD can find appropriate skin care, wound management, and infection prevention supplies through our skin care, wound care, and PPE catalogs.
